<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-029668
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20090804
<ITEMS>8.01
<FILING-DATE>20090804
<DATE-OF-FILING-DATE-CHANGE>20090804
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>MANNKIND CORP
<CIK>0000899460
<ASSIGNED-SIC>2834
<IRS-NUMBER>133607736
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-50865
<FILM-NUMBER>09984500
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
<PHONE>6617755300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v53147e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date
of Report (Date of earliest event reported): August&nbsp;4, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>MannKind Corporation</B></DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-50865</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3607736</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>28903 North Avenue Paine</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Valencia, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>91355</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(661)&nbsp;775-5300</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>N/A</B><BR>
(Former name or former address, if changed since last report.)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In this Report, the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MannKind Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are filing the following information with the Securities and Exchange Commission for the purpose
of updating certain aspects of our publicly disclosed descriptions of
our business and outstanding shares.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OUR
BUSINESS</B>
</DIV>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    MannKind Corporation is a biopharmaceutical company focused on
    the discovery, development and commercialization of therapeutic
    products for diseases such as diabetes and cancer. Our lead
    product candidate is an ultra rapid-acting insulin known as
    AFRESA, which is also the trade name for the product that we
    have proposed to the United States Food and Drug Administration,
    or FDA. In March 2009, we submitted a new drug application, or
    NDA, to the FDA requesting approval of AFRESA for the treatment
    of adults with type 1 or type 2 diabetes for the control of
    hyperglycemia. The FDA accepted our NDA for filing in May 2009.
    We believe that the performance characteristics, unique
    kinetics, convenience and ease of use of AFRESA have the
    potential to change the way diabetes is treated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that a distinguishing characteristic of AFRESA is
    that it produces a profile of insulin levels in the bloodstream
    that approximates the insulin profile normally seen in healthy
    individuals immediately following the beginning of a meal, but
    which is absent in patients with diabetes. Specifically, AFRESA
    is rapidly absorbed into the bloodstream following inhalation,
    reaching peak levels within 12 to 14 minutes. As a result of
    this rapid absorption, most of the glucose-lowering activity of
    AFRESA occurs within the first three hours of
    administration&#160;&#151; which is generally when glucose
    becomes available from a meal&#160;&#151; instead of the much
    longer duration of action observed when insulin is injected
    subcutaneously. We believe that the relatively short duration of
    action of AFRESA reduces the need for patients to snack between
    meals in order to manage ongoing blood glucose excursions. In
    our clinical trials, we have observed that patients using AFRESA
    have achieved significant reductions in post-meal glucose
    excursions and significant improvements in overall glucose
    control, as measured by decreases in glycosylated hemoglobin, or
    A1C, levels, without the weight gain typically associated with
    insulin therapy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have conducted an extensive clinical program, involving more
    than 40 different studies of AFRESA. Approximately 5,300
    subjects participated in our clinical studies, of which more
    than 2,900 subjects were administered AFRESA. These studies were
    conducted in healthy volunteers, patients with type 1 and type 2
    diabetes as well as diabetic patients with renal dysfunction,
    liver dysfunction, chronic obstructive pulmonary disease, asthma
    and upper respiratory tract infections. In addition, we have
    completed construction and achieved operational readiness of our
    production facility in Danbury, Connecticut. We believe that our
    facility will satisfy the initial commercial demand for AFRESA.
    The facility also includes expansion space that will allow
    production capacity to be increased based on anticipated needs
    during the initial years of commercialization. We are preparing
    for pre-approval inspection of the facility by the FDA. We will
    only be able to market AFRESA in the United States once, and if,
    the FDA approves our application.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AFRESA utilizes our proprietary Technosphere formulation
    technology, which is based on a class of organic molecules that
    are designed to self-assemble into small particles onto which
    drug molecules can be loaded. Technosphere technology is not
    limited to insulin delivery. We believe it represents a
    versatile drug delivery platform that may allow pulmonary
    administration of certain drugs that currently require
    administration by injection. Beyond convenience, we believe the
    key advantage of drugs inhaled as Technosphere formulations is
    that they have been shown to be absorbed very rapidly into the
    arterial circulation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also developing therapies for the treatment of different
    types of cancer, which do not utilize our Technosphere platform.
    We are currently completing two clinical trials of our
    therapeutic cancer vaccines. We expect to announce the results
    of these trials by the end of 2009.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OUTSTANDING SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of June&nbsp;30, 2009, the number of shares of our common stock outstanding was 103,646,376. This
outstanding share number does not include, as of June&nbsp;30, 2009:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>5,476,258 shares of common stock issuable upon the exercise of outstanding stock options
with a weighted average exercise price of $7.06 per share;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>3,595,482 shares of common stock issuable upon the settlement of outstanding restricted
stock units;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>5,117,523 shares of common stock issuable upon the conversion of our outstanding 3.75%
senior convertible notes due 2013 at a conversion price of approximately $22.47 per share;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2,882,873 shares of common stock reserved for issuance upon the exercise of outstanding
warrants with a weighted average exercise price of $12.23 per share; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>9,487,966 shares of common stock available for future grant under our 2004 equity
incentive plan, 2004 non-employee directors&#146; stock option plan and 2004 employee stock
purchase plan.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Forward-Looking
Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Certain statements in this Report are forward-looking
statements that involve a number of risks and uncertainties. Such forward-looking statements include, but are
not limited to, statements about: the potential for AFRESA, the progress or success of our research,
development and clinical programs for AFRESA, the timing or success of the commercialization of AFRESA,
our ability to market, commercialize and achieve market acceptance for AFRESA, the adequacy of our production
facility, the demand for AFRESA, our expected announcement of clinical trial results, our estimates for
future performance, scientific studies and the conclusions we draw from them and our pending public
offering of common stock. In some cases, you can identify forward-looking statements by terms such
as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148;
&#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148;
&#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions intended to identify forward-looking
statements. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from our expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include, but are not limited to, risks related to the
progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory
approval, the manufacture of AFRESA, competition from other pharmaceutical or biotechnology companies,
MannKind&#146;s ability to enter into any collaborations or strategic partnerships, intellectual property
matters, stock price volatility, inherent in attempting to engage in a public offering of common stock,
particularly in the current market environment, and other risks. Additional factors that could cause actual
results to differ materially from those stated or implied by our forward-looking statements are disclosed in our
filings with the Securities and Exchange Commission. These forward-looking statements represent our judgment
as of the time of this report. We disclaim any intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>MANNKIND CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David Thomson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Thomson, Ph.D., J.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Corporate Vice President, General Counsel
and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated:
August&nbsp;4, 2009
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
